View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 24, 2011

Study Says Heplisav is Superior to Engerix-B

A Phase III study of a hepatitis B virus vaccine Heplisav undertaken by Dynavax Technologies demonstrated superiority and safety compared to Engerix-B. Heplisav vaccine combines hepatitis B surface antigen with a proprietary toll-like receptor 9 agonist, known as ISS, to enhance immune

By cms admin

A Phase III study of a hepatitis B virus vaccine Heplisav undertaken by Dynavax Technologies demonstrated superiority and safety compared to Engerix-B.

Heplisav vaccine combines hepatitis B surface antigen with a proprietary toll-like receptor 9 agonist, known as ISS, to enhance immune response.

The trial involved 2,449 healthy adults between aged 40-70 and evaluated a two-dose regimen of Heplisav administered at zero and one month, compared with a three-dose regimen of Engerix-B administered at zero, one and six months.

The study demonstrated that at the primary endpoint, the seroprotection rate was 90% for Heplisav compared to 70% for Engerix-B.

In the study Heplisav was found to be safe and well-tolerated.

The complete results of the Phase III trial will be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy on 18 September in Chicago, US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology